HICKMAN CATHETER. HICKMAN CATHETER Thrombotic complications associated with venous access devices Occlusion of lumen Fibrin sheath formation Venous.

Slides:



Advertisements
Similar presentations
Venous Thromboembolism: Risk Assessment and Prophylaxis
Advertisements

Venous Thromboembolism Prevention August Venous Thromboembloism Prevention 2 Expected Practice  Assess all patients upon admission to the ICU for.
Prophylaxis of Venous Thromboembolism
Venous thromboembolism –
Perioperative Medicine Beyond Cardiac Clearance Pamela Pride MD July 31, 2012 MUSC.
Spotlight Case Breakage of a PICC Line.
CHEST-2012: High Points and Pearls Alan Brush, MD, FACP Chief, Anticoagulation Management Service Harvard Vanguard Medical Associates.
DPT 732 SPRING 2009 S. SCHERER Deep Vein Thrombosis.
Deep vein thrombosis. Color duplex scan of DVT Venogram shows DVT.
LIFEBLOOD THE Thrombosis CHARITY Venous thromboembolism – Treatment and secondary prevention Ulcus cruris Chronic PE PE DVT Post-thrombotic syndrome Death.
Unprovoked DVT in a young patient
 Introduced in early 1980s  Allow medications to be delivered directly into larger veins  Less likely to clot  Can be left in for longer periods of.
PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM
Management of Catheter-Related Complications: Perspective of an Interventional Radiologist Thomas M. Vesely, M.D. Mallinckrodt Institute of Radiology Washington.
Venous Thromboembolism
7th ACCP Conference on Antithrombotic and Thrombolytic Therapy: Evidence-Based Guidelines.
Originally Created By: Sheila Elliott MN, RN Revised By: Tina Haayer, RN, BScN.
Venous acess care Learning objectives –Learn about different cetral venous access devices (CVAD) –Catheter related complications of infectious and mechanical.
Pulmonary Embolism Treatment in Cancer - Is It Different 34th Brazilian Thoracic Conference 6th ALAT Congress 5th Brazil-Portugal Congress Brazilia/DF.
MANAGEMENT OF POST-ENDOVENOUS ABLATION VENOUS THROMBOSIS Stephen F. Daugherty, MD, FACS Clarksville, Tennessee, USA.
HICKMAN CATHETER Thrombotic complications associated with venous access devic Thrombotic complications associated with venous access devices Occlusion.
A.M.I. Infusion Port Products Trouble shooting Vascular Access Devices (by Diane Welker / Rush University College of Nursing / Chicago / Illinois) 1.
Deep vein thrombosis Pulmonary embolism Deep vein thrombosis Pulmonary embolism Venous Thromboembolism TreatmentTreatment …All the same?
Risk Assessment for VTE. Which of the following best describes you?
Duration of Anticoagulation 5 Patients Categories 3. First Episode: 4. First Episode: 5.Recurrent DVT 2. First Episode: 1. First Episode: Transient risk.
بسم الله الرحمن الرحيم. T. J. A IS STRONG PROPENSITY FOR T. E COMPLICATION THAT IS POTENTIALLY LIFE - THREATENING.
Venous Thromboembolism (VTE) Prophylaxis at Cesarean Section Phillip N. Rauk, MD.
Antithrombotic Therapy for VTE: CHEST Guidelines 2016
Maile Parker, MSIV University of Washington School of Medicine Sept. 27, 2012 Venous Thromboembolism Prophylaxis in Pediatric Patients With Central Venous.
Antithrombotic and Thrombolytic Therapy for Valvular Disease Copyright: American College of Chest Physicians 2012 © Antithrombotic Therapy and Prevention.
Jean‑Jacques Parienti, M.D., Ph.D., Nicolas Mongardon, M.D.,
Prevention of Venous Thromboembolism in Nonsurgical Patients Copyright: American College of Chest Physicians 2012 © Antithrombotic Therapy and Prevention.
Six Months vs Extended Oral Anticoagulation After a First Episode of Pulmonary Embolism ‘ The PADIS-PE Trial’ Nate Peyton.
Conclusions Results Methods Background Venous thrombo-embolism in patients undergoing neo- adjuvant chemotherapy and surgery for oesophago-gastric cancer.
Sclerotherapy and thrombophilia: How to do it? Saturday 29 March 2014 Pascal Giordana Nice, France.
Antithrombotic and Thrombolytic Therapy for Valvular Disease Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest.
Dr. Lesbia Adalgisa Rodriguez PGY3-Cook County Loyola Family Medicine Residency Program Venous Thromboembolism Prophylaxis in the Inpatient Setting.
Prevention of Venous Thromboembolism in Nonsurgical Patients Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest.
Outpatient DVT assessment & treatment Daniel Gilada.
Accuracy and usefulness of a clinical prediction rule and D-dimer testing in excluding deep vein thrombosis in cancer patients Thrombosis Research (2008)
VTE prophylaxis Sharif-Kashani,B.MD SBMU Preventing VTE Over 12 million people in the United States are at risk of VTE due to hospitalization for major.
Introduction - Perioperative management of patients on warfarin or antiplatelet therapy involves assessing and balancing individual risks for thromboembolism.
Recommendations for Catheter-to-Vein Ratio
Venous Thromboembolism Prophylaxis for Medical Inpatients
Deep Venous Thrombosis Anthony J. Comerota, MD, FACS, FACC
کزین برتر اندیشه بر نگذرد
By: Dr. Nalaka Gunawansa
The efficacy and safety of oral Rivaroxaban in patients with permanent inferior vena cava filter: a pilot case-control study Lobastov K., Barinov V.,
Treatment and Prevention of Heparin-Induced Thrombocytopenia
UNDERSTANDING YOUR RISK FOR DEVELOPING BLOOD CLOTS (VTE) IN CANCER
APEX Trial design: Patients hospitalized with an acute medical illness were randomized to oral betrixaban for days (n = 3,759) versus subcutaneous.
Anticoagulants in the Treatment of Venous Thromboembolism
Dr.H.Chandrashekar, Dr.A.Chaudhuri, Dr. A. Douglas, Dr. D. Lowdon
VTE Management Issues In Malignancy
UNDERSTANDING YOUR RISK FOR DEVELOPING BLOOD CLOTS (VTE) IN CANCER
Dr Ferdous Mehrabian. Dr Ferdous Mehrabian Inherited thrombophilias in pregnancy Inherited thrombophilias is a genetic tendency to venous thrombosis.
Prevention of Venous Thromboembolism in Orthopedic Surgery Patients
Central venous line–related thrombosis in children: association with central venous line location and insertion technique by Christoph Male, Peter Chait,
Thrombosis, Cancer, and NOACs
Owen N. Johnson, MD, David L
New Oral Anticoagulants and VTE Management
Prevention and Management of Venous Thromboembolic Events in Patients With Multiple Myeloma.
Cancer-Associated Thrombosis
Extraordinary Cases in VTE
How I treat cancer-associated venous thromboembolism
Treatment and secondary prevention strategy diagram for VTE in patients with active cancer based on the treatment guidelines for cancer-associated VTE.
Thrombophilia in pregnancy: Whom to screen, when to treat
VTE Treatment and Secondary Prevention VTE Treatment Trials Initial Dosing.
Prevention and Management of Venous Thromboembolic Events in Patients With Multiple Myeloma.
Treatment algorithm. Treatment algorithm. (A) Suggested treatment algorithm for symptomatic and incidental DVT or PE in cancer patients. (B) Suggested.
Presentation transcript:

HICKMAN CATHETER

Thrombotic complications associated with venous access devices Occlusion of lumen Fibrin sheath formation Venous thrombosis May occur at exit/entrance site, catheter tip, or anywhere in between

Intraluminal Fibrin sheath Venous thrombus

CATHETER THROMBOSIS Incidence of thrombosis ~10-15% Risk with port less than half of that with PICC line Risk increased 2 fold if prior hx of VTE Risk increased 2 fold if catheter tip malpositioned Bigger catheter (more lumens) → more risk Association with catheter infection Lower risk in patients having myeloablative chemotherapy (thrombocytopenia) Saber et al, 2009

Thrombosis-free survival of venous access devices Saber et al, 2009

Risk factors Catheter composition Catheter size Percutaneous insertion Prior catheter insertion L sided placement Subclavian vs internal jugular Infection Extrinsic vein compression Thrombophilia? Prior DVT Certain cancers (ovarian) Asparaginase Rx Estrogen Rx Erythropoietic agent Rx Thalidomide Rx Heparin-induced thrombocytopenia

Single-lumen and smaller diameter PICC lines cause less symptomatic DVT DVT incidence Chest 2013;143:627-633

Diagnosis Signs and symptoms Venography Ultrasound (has limitations) CT angio or MRI/MRA

Prophylaxis Low dose warfarin Probably ineffective Intermediate- or full-dose warfarin not adequately studied, likely effective given efficacy in other settings LMWH Dose? Duration? Target-specific oral agent? Routine prophylaxis not recommended in latest ACCP guidelines Consider if prior hx cathether thrombosis or other thrombotic complications

Management of symptomatic catheter-associated venous thrombosis Catheter removed? Y N Symptoms resolved? Anticoagulate until removal is possible N Y Short course of anticoagulation vs observation Anticoagulate 6-12 weeks